Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial. Issue 10 (October 2022)
- Record Type:
- Journal Article
- Title:
- Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial. Issue 10 (October 2022)
- Main Title:
- Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial
- Authors:
- Reiff, Tilman
Eckstein, Hans-Henning
Mansmann, Ulrich
Jansen, Olav
Fraedrich, Gustav
Mudra, Harald
Böckler, Dittmar
Böhm, Michael
Debus, E Sebastian
Fiehler, Jens
Mathias, Klaus
Ringelstein, Erich B
Schmidli, Jürg
Stingele, Robert
Zahn, Ralf
Zeller, Thomas
Niesen, Wolf-Dirk
Barlinn, Kristian
Binder, Andreas
Glahn, Jörg
Hacke, Werner
Ringleb, Peter Arthur
Beyersdorf, Friedhelm
Macharzina, Roland-Richard
Lechner, Gabriele
Menz, Carolin
Schonhardt, Sabine
Weinbeck, Michael
Greb, Olga
Otto, Dagmar
Winker, Thomas
Berger, Hermann
Poppert, Holger
Kühnl, Andreas
Pütz, Volker
Haase, Kathrin
Bodechtel, Ulf
Weiss, Norbert
Bergert, Hendrik
Meyne, Johannes
Groß, Justus
Kruse, Matthias
Gerdes, Berthold
Reinbold, Wolf-Dieter
Wuttig, Helge
Maier-Hasselmann, Andreas
Segerer, Manuela
Fuchs, Hans-Hermann
Gass, Sabine
Groden, Christoph
Niedergethmann, Marco
Griebe, Martin
Rosenkranz, Michael
Beck, Jürgen
Thomalla, Götz
Zeumer, Hermann H.
Jauß, Marek
Kneist, Werner
Kneist, Martina
Staudacher, Thomas
Bernhard, Alfons
Jost, Petra
Prey, Nico
Knippschild, Jürgen
Kastrup, Oliver
Köhrmann, Martin
Frank, Benedikt
Bongers, Volkmar
Hoffmann, Johannes
Kniemeyer, Horst-Wilhelm
Knauth, Michael
Wasser, Kathrin
Stojanovic, Tomislav
Emmert, Hans
Tacke, Josef
Schwalbe, Bernhard
Nam, Eun-Mi
van Lengerich, Ulrike
Lowens, Stephan
Gröschel, Klaus
Uphaus, Timo
Gröschel, Sonja
Boor, Stephan
Dorweiler, Bernhard
Schmid, Elisabeth
Henkes, Hans
Hupp, Thomas
Singer, Oliver
Hamann, Gerhard
Wagner-Heck, Michaela
Kerth-Krick, Sibylle
Kilic, Metin
Huppert, Peter
Niederkorn, Kurt
Fruhwirth, Johannes
Klein, Günther
Pulkowski, Ulrich
Jöster, Karsten
Wacks, Jens-Henning
Kloppmann, Egbert
Vatankhah, Bijan
Hopf-Jensen, Silke
Stolze, Henning
Müller-Hülsbeck, Stefan
Walluscheck, Knut Peer
Schmitt, Hans-Michael
Grüger, Albert
Seemann, Jörg
Tilahun, Belay
Dichgans, Martin
Wollenweber, Frank Arne
Dörr, Angelika
Zollver, Adelgunde
Gäbel, Gabor
Hedtmann, Günter
Kollmar, Rainer
Claus, Detlef
Petermann, Christian
Kirsch, Stefanie
Bosnjak, Branko
Heiß, Johannes
Mühling, Holger
Wunderlich, Silke
Sabisch, Peter Nikolaus
Gahn, Georg
Storck, Martin
Arnold, Sebastian
Fischer, Urs
Gralla, Jan
von Mering, Matthias
Dißmann, Rüdiger
Kirsch, Delia
Schmidauer, Christoph
Waldenberger, Peter
Furtner, Martin
Kazarians, Haiko
Breuer, Peter
Arning, Christian
Rieper, Jürgen
Schmidt, Georg
Arnold, Marcel
Schroth, Gerhard
Weise, Jens
Zanow, Jürgen
Mayer, Thomas
Töpper, Rudolf
Gross-Fengels, Walter
Daum, Harald
Dittrich, Ralf
Ritter, Martin
Kasprzak, Bernd
Torsello, Giovanni
Pohlmann, Carsten
Brüning, Roland
Breuer, Peter
Crispin, Alexander
Hofmann, Miriam
Müller, Thomas
Blessing, Erwin
Möhlenbruch, Markus
Ludwig, Ines
Amiri, Hemasse
… (more) - Abstract:
- Summary: Background: The optimal treatment for patients with asymptomatic carotid artery stenosis is under debate. Since best medical treatment (BMT) has improved over time, the benefit of carotid endarterectomy (CEA) or carotid artery stenting (CAS) is unclear. Randomised data comparing the effect of CEA and CAS versus BMT alone are absent. We aimed to directly compare CEA plus BMT with CAS plus BMT and both with BMT only. Methods: SPACE-2 was a multicentre, randomised, controlled trial at 36 study centres in Austria, Germany, and Switzerland. We enrolled participants aged 50–85 years with asymptomatic carotid artery stenosis at the distal common carotid artery or the extracranial internal carotid artery of at least 70%, according to European Carotid Surgery Trial criteria. Initially designed as a three-arm trial including one group for BMT alone (with a randomised allocation ratio of 2·9:2·9:1), the SPACE-2 study design was amended (due to slow recruitment) to become two substudies with two arms each comparing CEA plus BMT with BMT alone (SPACE-2a) and CAS plus BMT with BMT alone (SPACE-2b); in each case in a 1:1 randomisation. Participants and clinicians were not masked to allocation. The primary efficacy endpoint was the cumulative incidence of any stroke or death from any cause within 30 days or any ipsilateral ischaemic stroke within 5 years. The primary safety endpoint was any stroke or death from any cause within 30 days after CEA or CAS. The primary analysis was bySummary: Background: The optimal treatment for patients with asymptomatic carotid artery stenosis is under debate. Since best medical treatment (BMT) has improved over time, the benefit of carotid endarterectomy (CEA) or carotid artery stenting (CAS) is unclear. Randomised data comparing the effect of CEA and CAS versus BMT alone are absent. We aimed to directly compare CEA plus BMT with CAS plus BMT and both with BMT only. Methods: SPACE-2 was a multicentre, randomised, controlled trial at 36 study centres in Austria, Germany, and Switzerland. We enrolled participants aged 50–85 years with asymptomatic carotid artery stenosis at the distal common carotid artery or the extracranial internal carotid artery of at least 70%, according to European Carotid Surgery Trial criteria. Initially designed as a three-arm trial including one group for BMT alone (with a randomised allocation ratio of 2·9:2·9:1), the SPACE-2 study design was amended (due to slow recruitment) to become two substudies with two arms each comparing CEA plus BMT with BMT alone (SPACE-2a) and CAS plus BMT with BMT alone (SPACE-2b); in each case in a 1:1 randomisation. Participants and clinicians were not masked to allocation. The primary efficacy endpoint was the cumulative incidence of any stroke or death from any cause within 30 days or any ipsilateral ischaemic stroke within 5 years. The primary safety endpoint was any stroke or death from any cause within 30 days after CEA or CAS. The primary analysis was by intention-to treat, which included all randomly assigned patients in SPACE-2, SPACE-2a, and SPACE-2b, analysed using meta-analysis of individual patient data. We did two-step hierarchical testing to first show superiority of CEA and CAS to BMT alone then to assess non-inferiority of CAS to CEA. Originally, we planned to recruit 3640 patients; however, the study had to be stopped prematurely due to insufficient recruitment. This report presents the primary analysis at 5-year follow-up. This trial is registered with ISRCTN, number ISRCTN78592017. Findings: 513 patients across SPACE-2, SPACE-2a, and SPACE-2b were recruited and surveyed between July 9, 2009, and Dec 12, 2019, of whom 203 (40%) were allocated to CEA plus BMT, 197 (38%) to CAS plus BMT, and 113 (22%) to BMT alone. Median follow-up was 59·9 months (IQR 46·6–60·0). The cumulative incidence of any stroke or death from any cause within 30 days or any ipsilateral ischaemic stroke within 5 years (primary efficacy endpoint) was 2·5% (95% CI 1·0–5·8) with CEA plus BMT, 4·4% (2·2–8·6) with CAS plus BMT, and 3·1% (1·0–9·4) with BMT alone. Cox proportional-hazard testing showed no difference in risk for the primary efficacy endpoint for CEA plus BMT versus BMT alone (hazard ratio [HR] 0·93, 95% CI 0·22–3·91; p=0·93) or for CAS plus BMT versus BMT alone (1·55, 0·41–5·85; p=0·52). Superiority of CEA or CAS to BMT was not shown, therefore non-inferiority testing was not done. In both the CEA group and the CAS group, five strokes and no deaths occurred in the 30-day period after the procedure. During the 5-year follow-up period, three ipsilateral strokes occurred in both the CAS plus BMT and BMT alone group, with none in the CEA plus BMT group. Interpretation: CEA plus BMT or CAS plus BMT were not found to be superior to BMT alone regarding risk of any stroke or death within 30 days or ipsilateral stroke during the 5-year observation period. Because of the small sample size, results should be interpreted with caution. Funding: German Federal Ministry of Education and Research (BMBF) and German Research Foundation (DFG). … (more)
- Is Part Of:
- Lancet neurology. Volume 21:Issue 10(2022)
- Journal:
- Lancet neurology
- Issue:
- Volume 21:Issue 10(2022)
- Issue Display:
- Volume 21, Issue 10 (2022)
- Year:
- 2022
- Volume:
- 21
- Issue:
- 10
- Issue Sort Value:
- 2022-0021-0010-0000
- Page Start:
- 877
- Page End:
- 888
- Publication Date:
- 2022-10
- Subjects:
- Neurology -- Periodicals
Neurology -- Periodicals
Nervous System Diseases -- Periodicals
Neurologie -- Périodiques
Neurology
Electronic journals
Periodicals
616.805 - Journal URLs:
- http://www.thelancet.com/journals/laneur ↗
http://www.sciencedirect.com/science/journal/14744422 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/S1474-4422(22)00290-3 ↗
- Languages:
- English
- ISSNs:
- 1474-4422
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5146.084000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 23337.xml